J.P. Morgan analyst Anupam Rama has maintained their bullish stance on DAWN stock, giving a Buy rating on August 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anupam Rama has given his Buy rating due to a combination of factors that highlight the promising future of Day One Biopharmaceuticals. The anticipated steady growth of Ojemda in the recurrent or refractory pediatric low-grade glioma (r/r pLGG) setting is a significant factor, with peak sales projected to exceed $500 million in the U.S. alone. This growth potential is supported by the company’s confidence in new patient starts, persistence, and stable gross-to-net (GTN) ratios, which underpin their 2025 guidance of $140-150 million in sales.
Furthermore, the company has observed continued growth in new patient numbers quarter over quarter, with no expected slowdown. The GTN for Ojemda is expected to remain stable, even with a recent price increase, which should support revenue growth. Additionally, the upcoming update on the long-term safety and efficacy data from the FIREFLY-1 Cohort 1 study could further bolster investor confidence. These factors collectively contribute to the positive outlook and the Buy rating for Day One Biopharmaceuticals.
In another report released on August 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.